News
Bank of America Securities analyst Jason Gerberry reiterated a Sell rating on ProKidney yesterday and set a price target of $1.00. The company’s shares opened today at $4.82. Take advantage of ...
Ultragenyx is known for its focus on rare and ultra-rare genetic diseases, often targeting conditions that lack approved ...
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Shares of ProKidney Corp (NASDAQ: PROK) soared more than 25% in Thursday afternoon trading after the company reported ...
In a report released today, from Citi maintained a Buy rating on ProKidney, with a price target of $9.00. The company’s shares closed yesterday at $3.73. Take advantage of TipRanks Premium at 50% off!
Shares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase ...
ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday ...
ProKidney Corp. (PROK) shares just saw a massive green day. Results from Phase 2 were compelling and the data sharply ...
Live Updates Live Coverage Updates appear automatically as they are published. Wall Street Moves 9:53 am by Morgan Stanley ...
US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results ...
2d
InvestorsHub on MSNProKidney Shares Soar After Citi Lifts Price Target to $9Shares of ProKidney Corp. (NASDAQ:PROK) jumped 65% in pre-market trading Wednesday, extending the dramatic rally seen on ...
The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results